MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

por Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen, Henrik J. Ditzel
Publicado 2021